Abstract
Doxycycline post-exposure prophylaxis (doxy-PEP) for sexually transmitted bacterial infections reduces the risk of syphilis and chlamydia, but effectiveness against gonorrhea is variable, likely attributable to varying resistance rates. As doxy-PEP is incorporated into clinical practice, an urgent unanswered question is whether increased doxycycline use will drive tetracycline-class resistance in Neisseria gonorrhoeae. Here, we report an updated RT-PCR molecular diagnostic to detect the tetM gene that confers high-level tetracycline resistance in N. gonorrhoeae.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by R01AI132606 (to Y. H. G.), R01AI153521 (to Y. H. G.), contract 200-2016-91779 with the Centers for Disease Control and Prevention, and by the Pathogen Genomics Centers of Excellence Network. Wei Shen is supported by grants from the National Natural Science Foundation of China (32000474, 82341112), Chinese Scholarship Council scholarship (202308500105), and EMBL Visitor/Sabbatical Programme fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We received clinical isolates from the CDC/FDA Antimicrobial Resistance Isolate Bank, CDC's Gonococcal Isolate Surveillance Project (GISP) and Enhanced GISP (eGISP), and from a published study (PMID 36735316). Ethics statements are reproduced below from the reports of the original collection of these isolates. CDC GISP/eGISP: “The GISP/eGISP protocol is reviewed by the Office of the Associate Director for Science (ADS), NCHHSTP, CDC periodically. Most recently, this was done in February 2021 and both GISP and eGISP (Part A and Part B) were determined to be surveillance and disease control activities, and not human subjects research.” Published study PMID 36735316: “This research was deemed nonhuman subject research by the institutional review boards at the University of California San Diego, University of Washington, and Harvard T.H. Chan School of Public Health and therefore did not require institutional review board oversight.”
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
